Targets › CD11B
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology, Cardiovascular; next expected readout Dec 2026.
Integrin ITGAM/ITGB2 is implicated in various adhesive interactions of monocytes, macrophages and granulocytes as well as in mediating the uptake of complement-coated particles and pathogens. It is identical with CR-3, the receptor for the iC3b fragment of the third complement component. (UniProt, P11215)
Open in Phaseline: the race on CD11B, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Duke University | Tc 99m tilmanocept CD11b-targeting radiopharmaceutical; technetium-99m labeled molecular tracer that binds to | CD11B | Phase 2 | Cardiac Sarcoidosis | Dec 2026 |
| Washington University School of Medicine | ONT01 CD11b agonist | CD11B | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma | Sep 2028 |
Metastatic Pancreatic Ductal Adenocarcinoma (1) Cardiac Sarcoidosis (1)
small molecule (1), antibody (1)
Washington University School of Medicine (1) Duke University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.